Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ABTETH
Arcblock / Ethereum
crypto

Inactive
Dec 10, 2021 2:57:00 AM EST
0.00004027ETH+2.338%(+0.00000092)20,7120
OverviewHistoricalDepthTrendsNewsNews
Jan 7, 2022
09:00AM EST  Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)   PR Newswire
Oct 20, 2021
10:29AM EDT  A Crowded Earnings Calendar Ahead   Benzinga
Oct 7, 2021
08:17AM EDT  AbbVie's Upadacitinib (RINVOQ(r)) Met Primary and Most Ranked Secondary   PR Newswire
08:15AM EDT  AbbVie's RINVOQ(r) (upadacitinib) Met Primary and All Ranked Secondary   PR Newswire
Oct 2, 2021
06:07PM EDT  AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week   PR Newswire
Sep 30, 2021
08:30AM EDT  Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress   PR Newswire
Sep 23, 2021
08:45AM EDT  AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th   PR Newswire
Sep 16, 2021
08:01AM EDT  (RINVOQ(r)) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis   PR Newswire
Aug 24, 2021
08:01AM EDT  the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis   PR Newswire
Jun 28, 2021
08:45AM EDT  AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of   PR Newswire
Jun 25, 2021
02:30AM EDT  CHMP Recommends Approval of RINVOQ(r) (upadacitinib) for the Treatment of   PR Newswire
Jun 2, 2021
07:30AM EDT  Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress   PR Newswire
07:00AM EDT  in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress   PR Newswire
May 25, 2021
08:01AM EDT  AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data   PR Newswire
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
Jan 25, 2021
11:31AM EST  European Commission Approves AbbVie's RINVOQ(tm) (Upadacitinib) for the   PR Newswire
Dec 11, 2020
07:33AM EST  CHMP Recommends the Approvals of RINVOQ(tm) (Upadacitinib) for the Treatment of   PR Newswire
Oct 29, 2020
02:05AM EDT  AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ(tm)   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC